A Prospective, Comparative Study of Intravenous Iron Isomaltoside 1000 (Monofer®) Administered by Infusions to Non-Anaemic Patients Undergoing Elective or Sub-Acute Coronary Artery Bypass Graft, Valve Replacement or a Combination Thereof (CABG-01)

• ClinicalTrials.gov Identifier: NCT01563367
• Recruitment Status: Completed
• First Posted: March 27, 2012
• Last Update Posted: April 29, 2014
• Sponsor: Pharmacosmos A/S
• Collaborator: CRO Max Neeman
• Information provided by (Responsible Party): Pharmacosmos A/S

Study Description

Brief Summary:

The purpose of the study is to demonstrate that intravenous iron isomaltoside 1000 (Monofer®) is superior compared to placebo with respect to increasing the haemoglobin level in non-anaemic patients undergoing cardiac surgery

Condition or disease	Intervention/treatment	Phase
Non-anaemic Patients Undergoing Cardiac Surgery	Drug: Iron isomaltoside 1000 (Monofer®); Drug: Natriumklorid 9 mg/ml, Fresenius Kabi	Phase 3

Detailed Description:

The role of preoperative haemoglobin as a predictor of short-term and long-term outcomes after cardiac surgery has been well established. Anaemia can impede a patient's ability to recover fully and participate in postoperative rehabilitation. It has been found that patients with a normal haemoglobin level may become anaemic during surgery. An evaluation of patients undergoing cardiac surgery, i.e. CABG, valve or combined CABG-valve procedures showed that there was a decrease in mean haemoglobin level pre-surgery two and four days after surgery. To date, no prospective randomised clinical study in cardiac surgery assessing the effect of intravenous iron supplementation in patients undergoing cardiac surgery has been reported. This prospective, randomized, placebo controlled, double blind study is planned to evaluate the effect of intravenous iron isomaltoside 1000 (Monofer®) in comparison with placebo in non-anaemic patients undergoing cardiac surgery.

Study Design

• Study Type: Interventional (Clinical Trial)
• Actual Enrollment: 74 participants
• Allocation: Randomized
• Intervention Model: Parallel Assignment
• Masking: Double (Participant, Investigator)
• Primary Purpose: Treatment
• Official Title: A Randomized, Prospective, Double-Blind, Comparative Placebo-Controlled Study of Intravenous Iron Isomaltoside 1000 (Monofer®) Administered by Infusions to Non-Anaemic Patients Undergoing Elective or Sub-Acute CABG, Valve Replacement or a Combination Thereof
• Study Start Date: January 2012
• Actual Primary Completion Date: August 2013
• Actual Study Completion Date: September 2013

Arms and Interventions

Arm	Intervention/treatment
Active Comparator: Iron isomaltoside 1000 (Monofer®); Iron isomaltoside 1000 (Monofer®) - Intravenous Infusion	Drug: Iron isomaltoside 1000 (Monofer®); All subjects randomised to this group will receive 1000 mg iron isomaltoside 1000 as a single dose infusion administered over 15 minutes
Placebo Comparator: 0,9% sodium saline; Placebo (0.9% sodium saline) - Intravenous infusion	Drug: Natriumklorid 9 mg/ml, Fresenius Kabi; All subjects randomised to this group will receive an infusion of 100 ml 0.9% sodium chlorid administered over 15 min.; Other Name: 0.9% sodium chlorid.

Outcome Measures

Primary Outcome Measures :

1. Change in haemoglobin (Hb) concentrations [ Time Frame: From t=0 to t=4 weeks postoperatively ]
   To demonstrate that intravenous iron isomaltoside 1000 (Monofer®) is superior compared to placebo with respect to increasing the haemoglobin level in non- anaemic patients undergoing cardiac surgery

Secondary Outcome Measures :

1. Change in Hb concentrations [ Time Frame: t=0, t=5 days and t=4 weeks ]
   Proportion of patients that are anaemic (women < 12 g/dL and men < 13 g/dL) at day 5 and week 4
2. Number of patients in each randomisation group who need blood transfusion and number of transfusions administered [ Time Frame: From t=0 to t=day 5 and t=4 weeks ]
   To compare the number of patients who will need blood transfusion and number of transfusions in each randomisation group
3. Change in concentrations of serum ferritin, serum iron and Transferrin Saturation (TfS) TfS, and reticulocytes [ Time Frame: Change from baseline (preoperatively- the day before surgery or same day) in concentrations of serum ferritin, serum iron and Transferrin Saturation (TfS) TfS, and reticulocytes at 4 weeks and 3 months postoperatively ]
   From t=0 to t=day 5 and t=4 weeks
4. Number of postoperative days to discharge [ Time Frame: From t=0 to discharge ]
   To compare the number of days to discharge between the 2 randomisation groups
5. Changes in New York Heart Association (NYHA) classification [ Time Frame: From t=0 to t=4 weeks ]
   To compare the changes in New York Heart Association (NYHA) classification from baseline to 4 weeks postoperatively
6. Number of patients in each randomisation group who experience any study drug related adverse events (AEs/SAEs/SUSARs) [ Time Frame: From screening and until completion (t=-7 day and upto t=4 weeks) ]
   To compare the number of study drug related adverse events (AEs/SAEs/SUSARs) between subjects treated with iron isomaltoside 1000 (Monofer®) infusion and subjects treated with placebo infusion
7. Change in Hb [ Time Frame: t=0, t=day 5 and t=week 4 ]
   Proportion of patients able to maintain Hb between 9.5 and 12.5 g/dL (both values included) at day 5 and week 4

Eligibility Criteria

• Ages Eligible for Study: 18 Years and older (Adult, Older Adult)
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No

Criteria

Inclusion Criteria:

1. Men and women, aged more than 18 years.
2. Subjects undergoing elective or sub-acute CABG, valve replacement or a combination thereof
3. Female Hb ≥ 12.0 g/dl (7.45 mmol/l), Male Hb ≥ 13.0 g/dl (8.1 mmol/l).
4. Willingness to participate after informed consent.

Exclusion Criteria:

1. Subjects receiving blood transfusion less than 30 days before screening and/or during the elective or sub-acute CABG, valve replacement, or a combination thereof.
2. Iron overload or disturbances in utilization of iron (e.g. haemochromatosis and haemosiderosis).
3. Serum Ferritin > 800 ng/ml.
4. Known hypersensitivity to any excipients in the investigational drug products.
5. Patients with a history of multiple allergies.
6. Decompensated liver cirrhosis and hepatitis.
7. Alanine Aminotransferase (ALT) > 3 times normal upper value.
8. Acute infections (assessed by clinical judgement).
9. Rheumatoid arthritis with symptoms or signs of active joint inflammation.
10. Pregnant or nursing. (To avoid pregnancy, women have to be postmenopausal (at least 12 months must have elapsed since last menstruation), surgically sterile, or women of child bearing potential must use one of the following contraceptives during the whole study period and after the study has ended for at least 5 times plasma biological half-life of the investigational medicinal product: Contraceptive pills, Intrauterine Devices (IUD), contraceptive depot injections (prolonged-release gestagen), subdermal implantation, vaginal ring, and transdermal patches).
11. Participation in any other clinical trial where the study drug has not passed five half-lives prior to screening.
12. Untreated Vitamin B12 or folate deficiency.
13. Other IV or oral iron treatment within 4 weeks prior to screening visit.
14. Erythropoietin treatment within 4 weeks prior to screening visit
15. Impaired renal function defined by se-creatinin > 150 µmol/l

Contacts and Locations

Locations

Denmark

Copenhagen, Denmark

Sponsors and Collaborators

Pharmacosmos A/S

CRO Max Neeman

Investigators

• Study Chair: Lars Lykke Thomsen; Pharmacosmos A/S

More Information

• Responsible Party: Pharmacosmos A/S
• ClinicalTrials.gov Identifier: NCT01563367
• Other Study ID Numbers: P-Monofer-CABG-01
• First Posted: March 27, 2012
• Last Update Posted: April 29, 2014
• Last Verified: April 2014

Keywords provided by Pharmacosmos A/S:

Anaemia; Cardiac surgery

Additional relevant MeSH terms:

Iron isomaltoside 1000; Hematinics